

Welcome to the Integrated Research Application System

IRAS Project Filter

The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications.

Please complete the questions in order. If you change the response to a question, please select 'Save' and review all the questions as your change may have affected subsequent questions.

Please enter a short title for this project (maximum 70 characters)

SPRING - Seizure PRophylaxis IN Glioma

1. Is your project research?

Yes No

2. Select one category from the list below:

- Clinical trial of an investigational medicinal product
- Clinical investigation or other study of a medical device
- Combined trial of an investigational medicinal product and an investigational medical device
- Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
- Basic science study involving procedures with human participants
- Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative methodology
- Study involving qualitative methods only
- Study limited to working with human tissue samples (or other human biological samples) and data (specific project only)
- Study limited to working with data (specific project only)
- Research tissue bank
- Research database

If your work does not fit any of these categories, select the option below:

Other study

2a. Is this a commercially sponsored Phase 1 or Phase 1/2a trial involving healthy volunteers?

Yes No

2b. Will the study involve the use of any medical device without a CE Mark, or a CE marked device which has been modified or will be used outside its intended purposes?

Yes No

2c. Please answer the following question:

Is this trial subject to advice from the Expert Advisory Group on Clinical Trials and the Commission on Human Medicine prior to authorisation from MHRA?

Yes No

2d. Please answer the following question:

Is this a trial of a gene therapy medicinal product?

Yes No

2e. Please answer the following question(s):

a) Does the study involve the use of any ionising radiation?

Yes No

b) Will you be taking new human tissue samples (or other human biological samples)?

Yes No

c) Will you be using existing human tissue samples (or other human biological samples)?

Yes No

3. In which countries of the UK will the research sites be located?(Tick all that apply)

- England
- Scotland
- Wales
- Northern Ireland

3a. In which country of the UK will the lead NHS R&D office be located:

- England
- Scotland
- Wales
- Northern Ireland
- This study does not involve the NHS

4. Which applications do you require?

- IRAS Form
- Medicines and Healthcare products Regulatory Agency (MHRA) – Medicines
- Confidentiality Advisory Group (CAG)
- Her Majesty's Prison and Probation Service (HMPPS)

5. Will any research sites in this study be NHS organisations?

Yes No

5c. You have indicated that your study has sites located in England. For the research sites located in England, do you wish for the study to be considered for NIHR Clinical Research Network (CRN) support and inclusion in the NIHR Clinical Research Network (CRN) Portfolio? Please see information button for further details

Yes No

6. Do you plan to include any participants who are children?

Yes No

7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent for themselves?

Yes No

Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.

8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or who are offenders supervised by the probation service in England or Wales?

Yes No

9. Is the study or any part of it being undertaken as an educational project?

Yes No

10. Will this research be financially supported by the United States Department of Health and Human Services or any of its divisions, agencies or programs?

Yes No

11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project (including identification of potential participants)?

Yes No

SUBSTANTIAL AMENDMENT FORM ¹

NOTIFICATION OF A SUBSTANTIAL AMENDMENT TO A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE EUROPEAN UNION

For official use:

Date of receiving the request:	Grounds for non acceptance/negative opinion:
	Date:
Date of start of procedure:	Authorisation/ positive opinion:
	Date:
Competent authority registration number of the trial:	Withdrawal of amendment application:
Ethics committee registration number of the trial:	Date:

To be filled in by the applicant:

*This form is to be used both for a request to the Competent Authority for authorisation of a **substantial** amendment and to an Ethics Committee for its opinion on a **substantial** amendment. Please indicate the relevant purpose in Section A.*

A TYPE OF NOTIFICATION

A.1 Member State in which the substantial amendment is being submitted:

United Kingdom

A.2 Notification for authorisation to the competent authority:

A.3 Notification for an opinion to the ethics committee:

(¹) Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (OJ, C82, 30.3.2010, p.1) hereinafter referred to as 'detailed guidance CT-1'.

B TRIAL IDENTIFICATION (When the amendment concerns more than one trial, repeat this form as necessary.)

B.1 Does the substantial amendment concern several trials involving the same IMP? ² Yes No

B.2 EudraCT number: 2018-001312-30

B.3 Full title of the trial: SPRING: Seizure Prophylaxis IN Glioma

B.4 Sponsor's protocol code number:

B.4 Sponsor's protocol version number: 6.2

B.4 Sponsor's protocol date: 25/09/2019

(²) Cf. Section 3.7. of the detailed guidance CT-1

C IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

C.1 Sponsor

Organisation: Common Services Agency
 Contact Given name: Duncan
 Contact Family name: Buchanan
 Address: Gyle Square, 1 South Gyle Crescent
 Town/city: Edinburgh
 Post code: EH12 9EB
 Telephone: 01312756114
 Fax:
 E-mail: duncan.buchanan@nhs.net

C.2 Legal representative ³ of the sponsor in the European Union for the purpose of this trial (if different from the sponsor)

Name of organisation:
 Contact Given name:
 Contact Family name:
 Address:
 Town/city:
 Post code:
 Telephone:
 Fax:
 E-mail:

(3) As stated in Article 19 of Directive 2001/20/EC.

D APPLICANT IDENTIFICATION, (please tick the appropriate box)

D1. Request for the competent authority

- D.1.1 Sponsor
 D.1.2 Legal representative of the sponsor
 D.1.3 Person or organisation authorised by the sponsor to make the application.
 D.1.4 Complete below:

Name of organisation Common Services Agency
 Contact Given name Jackie
 Contact Family name Burns
 Address Gyle Square, 1 South Gyle Crescent
 Town/city Edinburgh
 Post code EH12 9EB
 Telephone 01312756101
 Fax
 E-mail jackieburns@nhs.net

D2. Request for the Ethics Committee

- D.2.1 Sponsor
- D.2.2 Legal representative of the sponsor
- D.2.3 Person or organisation authorised by the sponsor to make the application.
- D.2.4 Investigator in charge of the application if applicable⁴:
- Co-ordinating investigator (for multicentre trial):
 - Principal investigator (for single centre trial):
- D.2.5 Complete below:

Name of organisation Common Services Agency

Given name Jackie

Family name Burns

Address Gyle Square, 1 South Gyle Crescent

Town/city Edinburgh

Post code EH12 9EB

Telephone 01312756101

Fax

E-mail jackieburns@nhs.net

⁽⁴⁾ According to national legislation.

E SUBSTANTIAL AMENDMENT IDENTIFICATION

E.1 Sponsor's substantial amendment information for the clinical trial concerned:

Code Number: Substantial Amendment No.5

Version:

Date: 2020/04/07

E.2 Type of substantial amendment

- E.2.1 Amendment to information in the CT application form Yes No
- E.2.2 Amendment to the protocol Yes No
- E.2.3 Amendment to other documents appended to the initial application form Yes No

If yes specify:

Protocol (version 6.3, 07th April 2020)

Patient Information Sheet and Informed Consent Form (version 6.1, 07th April 2020)

- E.2.4 Amendment to other documents or information: Yes No

If yes specify:

Tablet Tracker for Compliance Reduced (version 2.0, 30th January 2020)

- E.2.5 This amendment concerns mainly urgent safety measures already implemented⁵: Yes No
- E.2.6 This amendment is to notify a temporary halt of the trial⁶: Yes No
- E.2.7 This amendment is to request the restart of the trial⁷: Yes No

⁽⁵⁾ Cf. Section 3.9. of the detailed guidance CT-1.

⁽⁶⁾ Cf. Section 3.10. of the detailed guidance CT-1

⁽⁷⁾ Cf. Section 3.10. of the detailed guidance CT-1

E.3 Reasons for the substantial amendment:

- E.3.1 Changes in safety or integrity of trial subjects Yes No
- E.3.2 Changes in interpretation of scientific documents/value of the trial Yes No
- E.3.3 Changes in quality of IMP(s) Yes No
- E.3.4 Changes in conduct or management of the trial Yes No
- E.3.5 Change or addition of principal investigator(s), co-ordinating investigator Yes No
- E.3.6 Change/addition of site(s) Yes No
- E.3.7 Other change Yes No

E.3.7.1 If yes specify:

Updated SmPC which includes changes to the Reference Safety Information, section 4.8

Undesirable Effects on the following dates:

14 March 2019

01 April 2019

30 October 2019

Updated PIS to reflect additional side effects added to section 4.8 of the SmPC

Updated protocol to reflect additional side effects added to section 4.8 of the SmPC and also to update the trial contacts.

Updated Tablet Tracker for Compliance Reduced, to amend typographical errors.

- E.3.8 Other case Yes No

E.3.8.1 If yes specify:

E.4 Information on temporary halt of trial:⁸

- E.4.1 Date of temporary halt
- E.4.2 Recruitment has been stopped Yes No
- E.4.3 Treatment has been stopped Yes No

E.4.4 Number of patients still receiving treatment at time of the temporary halt in the MS concerned by the amendment

E.4.5 Briefly describe:

Justification for a temporary halt of the trial (*free text*):

The proposed management of patients receiving treatment at time of the halt (*free text*):

The consequences of the temporary halt for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product (*free text*):

⁽⁸⁾Cf. Section 3.10. of the detailed guidance CT-1

F DESCRIPTION OF EACH SUBSTANTIAL AMENDMENT⁹

Please use this section to detail each substantial amendment which is being notified. If you are notifying more than one substantial amendment, please use the "Add Amendment" button as required

Substantial amendment 1

Previous and new wording:(tracked)

Summary of changes

1. SmPC 14 March 2019 - Section 4.8 Undesirable Effects: A new adverse reaction of gait disturbance has been added to the list of Nervous System Disorders, affecting between 1 in 1000 and 1 in 10000 people.
2. SmPC 01 April 2019 - Section 4.8 Undesirable Effects: A new adverse reaction of delirium has been added to the list of Psychiatric Disorders, affecting between 1 in 1000 and 1 in 10000 people.
3. SmPC 01 April 2019 - Section 4.8 Undesirable Effects: A new adverse reaction of encephalopathy has been added to the list of Nervous System Disorders, affecting between 1 in 1000 and 1 in 10000 people.
4. SmPC 04 October 2019 - Section 4.4 Special warnings and precautions for use of Keppra has been updated to include abnormal thoughts, feeling irritable or reacting more aggressively than usual or if patient or family or friends notice important changes in mood or behaviour.

The protocol and PIS have been updated to reflect these changes to the SmPC.

New wording:

See above

Comments/ explanation/ reasons for substantial amendment:

Amendments to section 4.8 of the SmPC has resulted in amendments to the protocol and the PIS.

⁽⁹⁾Cf. Section 3.7.c. of the detailed guidance CT-1. The sponsor may submit this documentation on a separate sheet.

G CHANGE OF CLINICAL TRIAL SITE(S)/INVESTIGATOR(S) IN THE MEMBER STATE CONCERNED BY THIS AMENDMENT

Type of change:

G.1.1 Addition of a new site

G.1.1.1 Principal investigator (provide details below)

Given name
Middle name(if
applicable)
Family name
Qualification
(MD...)
Professional
address

G.1.2 Removal of an existing site

G.1.2.1 Principal investigator (provide details below)

Given name
Middle name(if
applicable)
Family name
Qualification
(MD...)
Professional
address

G.1.3 Change of co-ordinating investigator (provide details below of the new coordinating investigator)

Given name
Middle name(if
applicable)
Family name
Qualification
(MD...)
Professional
address

G.1.3.6 Indicate the name of the previous co-ordinating investigator:

G.1.4 Change of principal investigator at an existing site (provide details below of the new principal investigator)

Given name
Middle name(if
applicable)
Family name
Qualification
(MD...)
Professional
address

G.1.4.6 Indicate the name of the previous principal investigator:

H CHANGE OF INSTRUCTIONS TO CA FOR FEEDBACK TO SPONSOR

H.1 Change of e-mail contact for feedback on application*

H.2 Change to request to receive an .xml copy of CTA data

Yes No

H.2.1 Do you want a .xml file copy of the CTA form data saved on EudraCT?

Yes No

H.2.1.1 If yes provide the e-mail address(es) to which it should be sent (up to 5 addresses):

H.2.2 Do you want to receive this via password protected link(s)¹⁰?

Yes No

If you answer no to question H.2.2 the .xml file will be transmitted by less secure e-mail link(s)

H.2.3 Do you want to stop messages to an email for which they were previously requested? Yes No

H.2.3.1 If yes provide the e-mail address(es) to which feedback should no longer be sent:

(*This will only come into effect from the time at which the request is processed in EudraCT).

(10) This requires a EudraLink account. (See eudract.emea.europa.eu for details)

I LIST OF THE DOCUMENTS APPENDED TO THE NOTIFICATION FORM (cf. Section 3.7 of detailed guidance CT-1)

Please submit only relevant documents and/or when applicable make clear references to the ones already submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).

- | | |
|--|-------------------------------------|
| I.1 Cover letter | <input checked="" type="checkbox"/> |
| I.2 Extract from the amended document in accordance with Section 3.7.c. of detailed guidance CT-1 (if not contained in Part F of this form) | <input type="checkbox"/> |
| I.3 Entire new version of the document¹¹ | <input checked="" type="checkbox"/> |
| I.4 Supporting information | <input type="checkbox"/> |
| I.5 Revised .xml file and copy of initial application form with amended data highlighted | <input type="checkbox"/> |
| I.6 Comments on any novel aspect of the amendment if any : | |

(11) Cf. Section 3.7.c. of the detailed guidance CT-1

J SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

Please submit only relevant documents and/or when applicable make clear references to the ones already submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).

J.1 I hereby confirm that/ confirm on behalf of the sponsor that (delete which is not applicable)

- The above information given on this request is correct;
- The trial will be conducted according to the protocol, national regulation and the principles of good clinical practice; and
- It is reasonable for the proposed amendment to be undertaken.

J.2 APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY(as stated in section D.1):

J.2.1 Signature ¹²:

J.2.2 Print name:

J.2.3 Date:

This section was signed electronically by Mr Duncan Buchanan on 14/04/2020 11:01.

Job Title/Post: Head of Service
Organisation: Public Health Scotland
Email: Duncan.Buchanan@nhs.net

J.3 APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE (as stated in section D.2):

J.3.1 Signature ¹³:

J.3.2 Print name:

J.3.3 Date:

This section was signed electronically by Mr Duncan Buchanan on 14/04/2020 11:05.

Job Title/Post: Head of Service
Organisation: Public Health Scotland
Email: Duncan.Buchanan@nhs.net

(12) On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.
(13) On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.